Founded on the ACC-project, the focus of OncoTargeting CA AB is severe indications with limited available treatment – where a limited research effort can make a difference. Orphan drug indications like ACC enable a minimalistic approach and a relatively short time for drug development. With an aggressive compound screening funnel and early efficacy assays, OncoTargeting CA AB focuses on lean drug development.